Personalis provides genetic tests for cancer. Co. also provides sequencing and data analysis services to support population sequencing initiatives. Co. operates and manages its business as one reportable operating segment, which is the sale of sequencing and data analysis services. Co.'s products include NeXT Platform, which is a platform that enable the analysis of both a tumor and its microenvironment from a single sample. Co. has created an ecosystem of products and capabilities built on the NeXT Platform: ImmunoID Next (tumor profiling from tissue), NeXT Liquid Biopsy (tumor profiling from plasma) and NeXT Personal (liquid biopsy providing for personalized tumor tracking for patients). The PSNL stock yearly return is shown above.
The yearly return on the PSNL stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PSNL annual return calculation with any dividends reinvested as applicable (on ex-dates).
|